atoms

Deinove

EG: ALDEI

€22.8m market cap

€1.06 last close

Deinove is a biotechnology company that discovers, develops and produces high value-added compounds using its state-of-the-art bacterial strain selection, banking, fermentation and screening facilities. The most valuable compounds in the pipeline are novel antimicrobials, with lead asset DNV3837 in a Phase II trial.

Investment summary

Deinove is running a Phase II study with the novel quinolonyl-oxazolidinone class antibiotic DNV3837 for moderate to severe C. diff infections. This is an open-label study that will be conducted in two parts in 15 centres in the US. Part two of the study will be randomised in up to 30 patients and will include efficacy endpoints. The company also reported multiple developments in its bioactives portfolio. The most recent development was the launch of Luminity, which is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion. As a metabolic intermediate of the formation of lycopene from phytoene, neurosporene is a carotenoid rarely found in nature, which is now commercially accessible and patent protected. Deinove confirmed Luminity’s effects in in vitro, ex vivo and clinical studies. In November, Deinove signed an evaluation and technology development programme with nutrition company DSM for a microbial strain identified in its Color-2B program; deal terms were not disclosed.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.8 (9.4) (10.5) (61.25) N/A N/A
2019A 0.6 (10.8) (12.2) (58.75) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

Environmentalism will underpin growth in green chemistry and growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 19/01/2021
Register to receive research on Deinove as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (€m) 14.7
Forecast gearing ratio (%) 164
Price performance
%
1m
3m
12m
Actual 53.3 67.5 17.0
Relative* 51.0 47.5 26.2
52-week high/low €1.2/€0.5
*% relative to local index
Key management
Dr Philippe Pouletty Chairman
Emmanuel Petiot CEO
Julien Coste CFO